Evaluation of thioredoxin reductase as a novel biomarker in the diagnosis and treatment of breast cancer

硫氧还蛋白还原酶作为新型生物标志物在乳腺癌诊断和治疗中的价值(英文)

Overexpression of thioredoxin reductase has been identified in a variety of primary tumors, suggesting the levels of TrxR activity between tumor patients and normal people are potentially different. Here, we performed a study to investigate the differences of TrxR activity between normal people and breast tumor patients, with the expectation that TrxR activity can be considered as a novel biomarker involved in breast cancer diagnosis and treatment. In this study, we have demonstrated for the first time that TrxR levels in breast cancer patients before therapy were significantly higher than those of normal people （P〈0.05）. No significant difference of TrxR activity was found among the patients at different stages of breast tumor progression. In the patient group of TrxR 〈10 U/mL, evaluation of TrxR activity has shown a high consistency with the results from cancer diagnostic imaging. Overall, these observations suggest TrxR as an effective biomarker to monitor and evaluate the clinical outcome of breast cancer therapeutics, and identify TrxR activity as a novel approach for breast cancer early-stage detection.

已有研究证明硫氧还蛋白还原酶在多种人原发肿瘤中过度表达,其活性在肿瘤人群和健康人群中有明显差异。本文研究了健康人群和乳腺癌患者中TrxR活性的不同,并探讨了硫氧还蛋白还原酶作为乳腺癌治疗中的一个新型治疗靶点的可能性。通过研究,我们第一次发现未经治疗的肿瘤患者的TrxR活性值水平明显高于健康人群。在乳腺癌患者中,TrxR活性值在不同的年龄组和癌症分期组没有明显的差异。当TrxR活性值小于10 U/mL时,TrxR活性值和肿瘤影像学评价结果有很高的一致性。这些发现证明硫氧还蛋白还原酶可以作为一个有效的新型生物标志物用于对乳腺癌临床治疗效果的监测和评价,并能成为乳腺癌早期检测的一种方法。